Kiyoshi KikuchiHisaaki UchikadoNaohisa MiyagiYoko MorimotoIto TakashiSalunya TancharoenNaoki MiuraKie MiyataRokudai SakamotoChiemi KikuchiNarumi IidaNaoto ShiomiTerukazu KuramotoK. Ichi KawaharaYame Public HospitalKurume University School of MedicineKagoshima University Faculty of MedicineMahidol UniversityKagoshima UniversityNishida Koutoku HospitalKohjin Co., Ltd.Saiseikai Shiga HospitalOmuta City General Hospital2018-05-032018-05-032011-12-01International Journal of Molecular Medicine. Vol.28, No.6 (2011), 899-9061791244X110737562-s2.0-80053510027https://repository.li.mahidol.ac.th/handle/20.500.14594/11423Free radicals play major roles in the pathogenesis of tissue damage in many diseases and clinical conditions, and the removal of free radicals may offer a treatment option. Several modulators of free radical scavenger pathways have been developed and some have progressed to clinical trials. One such agent, edaravone, was approved in 2001 in Japan for the treatment of cerebral infarction. It has since been shown that edaravone can diffuse into many organs and, in addition to its effects on hydroxyl radical removal, edaravone modulates inflammatory processes, matrix metalloproteinase levels, nitric oxide production, apoptotic cell death, and necrotic cell death. Edaravone also exerts protective effects in a number of animal models of disease and tissue damage, including models of myocardial, lung, intestinal, liver, pancreatic and renal injury. Together with the proven safety of edaravone following 9 years of use as a modulator of free radical scavenging pathways in neurological disease, these additional effects of edaravone suggest that it may offer a novel treatment for several non-neurological diseases and clinical conditions in humans.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyReviewSCOPUS10.3892/ijmm.2011.795